Cargando…

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Detalles Bibliográficos
Autores principales:	Pancholi, Sunil, Leal, Mariana Ferreira, Ribas, Ricardo, Simigdala, Nikiana, Schuster, Eugene, Chateau-Joubert, Sophie, Zabaglo, Lila, Hills, Margaret, Dodson, Andrew, Gao, Qiong, Johnston, Stephen R., Dowsett, Mitch, Cosulich, Sabina C., Marangoni, Elisabetta, Martin, Lesley-Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993431/ https://www.ncbi.nlm.nih.gov/pubmed/32005287 http://dx.doi.org/10.1186/s13058-020-1254-5

Ejemplares similares

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2019)

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
por: Ribas, Ricardo, et al.
Publicado: (2018)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
por: Pancholi, Sunil, et al.
Publicado: (2020)

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
por: Yeo, B, et al.
Publicado: (2015)

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models
por: Wong Te Fong, Anne-Christine, et al.
Publicado: (2017)

Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
por: Guest, Stephanie K., et al.
Publicado: (2016)

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
por: Simigdala, Nikiana, et al.
Publicado: (2018)

Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2
por: Jordan, Justin T, et al.
Publicado: (2023)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
por: Simigdala, Nikiana, et al.
Publicado: (2016)

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo
por: Martin, Lesley-Ann, et al.
Publicado: (2012)

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
por: Ribas, Ricardo, et al.
Publicado: (2014)

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
por: Osborne, C K, et al.
Publicado: (2004)

mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)

Who would have thought a single Ki67 measurement would predict long-term outcome?
por: Dowsett, Mitch, et al.
Publicado: (2009)

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015)

The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling
por: Merhi, Ahmad, et al.
Publicado: (2017)

mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Ding, Xiaolei, et al.
Publicado: (2016)

LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
por: Ribeiro, Marcelle C., et al.
Publicado: (2018)

mTORC1 and mTORC2 differentially promote natural killer cell development
por: Yang, Chao, et al.
Publicado: (2018)

mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
por: Yang, Jin Young, et al.
Publicado: (2019)

Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
por: Kosillo, Polina, et al.
Publicado: (2022)

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
por: Basu, B, et al.
Publicado: (2018)

ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data
por: Robertson, J F R
Publicado: (2001)

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
por: Luo, Yan, et al.
Publicado: (2015)

Regulation of Autophagy through TORC1 and mTORC1
por: Noda, Takeshi
Publicado: (2017)

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
por: Langdon, Sophie, et al.
Publicado: (2018)

Glutaminolysis feeds mTORC1
por: Durán, Raúl V., et al.
Publicado: (2012)

Regulation of adiposity by mTORC1
por: Magdalon, Juliana, et al.
Publicado: (2017)

Regulation of mTORC2 Signaling
por: Fu, Wenxiang, et al.
Publicado: (2020)

mTORC2 Steals the Spotlight
por: Jansen, Laura A.
Publicado: (2020)

Something to mTORC About in NASH
por: Finck, Brian N.
Publicado: (2022)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors
por: Zhu, Ping Jun, et al.
Publicado: (2018)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
por: Feldman, Morris E, et al.
Publicado: (2009)

Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication
por: Kuss-Duerkop, Sharon K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h4ktujlsug6gv34idab1j7b5rl